Biomerica Launches inFoods IBS in Canada Targeting 5M Patients with 18% Prevalence
Biomerica has launched its inFoods IBS diagnostic-guided therapy in Canada via exclusive distribution partnership with Phoenix Airmid and lab processing by CanAlt Health Labs, marking its first commercial entry. Canada’s IBS prevalence of ~18% (up to 5 million patients) presents a significant market opportunity for its personalized, non-pharmaceutical solution.
1. Canadian Market Launch
Biomerica has officially introduced its inFoods IBS platform in Canada, marking its first international commercial expansion. The launch establishes a local presence for the company’s precision diagnostic-guided therapy designed to identify food triggers for gastrointestinal symptoms.
2. Strategic Partnerships
Phoenix Airmid Biomedical will serve as the exclusive distribution partner, managing sales and physician outreach, while CanAlt Health Labs will process patient samples through its certified laboratory infrastructure. These agreements create a scalable commercial framework from day one.
3. Significant Market Opportunity
With an estimated 18% IBS prevalence rate—affecting up to 5 million Canadians—and incremental annual healthcare costs of roughly USD 2,026 per patient, Canada represents a substantial underserved market for a non-pharmaceutical IBS solution.
4. Clinical Efficacy Data
A multicenter, double-blind study published in mid-2025 showed 59.6% of inFoods IBS patients achieved FDA responder criteria for abdominal pain reduction versus 42.2% in the control group (p=0.02), supporting the platform’s targeted dietary approach.